Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fludeoxyglucose F-18

FDA-approved product (injectable, injection), marketed as Fludeoxyglucose F18.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Fludeoxyglucose F-18
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Fludeoxyglucose F-18. Its therapeutic class is shown instead.

WHO therapeutic group
Other diagnostic radiopharmaceuticals for tumour detection
FDA pharmacologic class
Radioactive Diagnostic Agent FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Fludeoxyglucose F-18, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA18.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli6.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis13.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fludeoxyglucose F-18 in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fludeoxyglucose F-18 with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • (89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma

    NCT05747625 · start 2023-05-09

    Registered record
    Registry ID
    NCT05747625
    Conditions
    Head and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Panitumumab; Zirconium Zr 89 Panitumumab; Positron Emission Tomography; Computed Tomography; Electronic Health Record Review
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-05-09
    Completion
    2030-03-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHead and Neck Squamous Cell Carcinoma; Metastatic Head and Neck Squamous Cell Carcinoma; Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck
    InterventionPanitumumab; Zirconium Zr 89 Panitumumab; Positron Emission Tomography; Computed Tomography +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Characterization of priMary And sEcondary STress Related takOtsubo

    NCT05793008 · start 2023-03-30

    Registered record
    Registry ID
    NCT05793008
    Conditions
    Takotsubo Cardiomyopathy; Sepsis-induced Cardiomyopathy
    Interventions
    Positron Emission Tomography (PET) analysis; Blood samples collection; Clinical follow up visit
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2023-03-30
    Completion
    2026-09-02
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTakotsubo Cardiomyopathy; Sepsis-induced Cardiomyopathy
    InterventionPositron Emission Tomography (PET) analysis; Blood samples collection; Clinical follow up visit
    PhaseNot applicable
    Registry statusUnknown

  • Activation of Brown Adipose Tissue Thermogenesis in Humans Using Formoterol Fumarate (GB10)

    NCT05553184 · start 2022-07-05

    Registered record
    Registry ID
    NCT05553184
    Conditions
    Type 2 Diabetes; Obesity
    Interventions
    Formoterol Fumarate 12 micrograms Inhalation Powder; Nicotinic Acid 50 MG Oral Tablet; Acute Cold Exposure; Positron Emission Tomography (PET); Indirect calorimetry; dual-energy x-ray absorptiometry (DEXA scan); Biopsy; iv lines; Electromyogram (EMG)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-07-05
    Completion
    2023-05-29
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Obesity
    InterventionFormoterol Fumarate 12 micrograms Inhalation Powder; Nicotinic Acid 50 MG Oral Tablet; Acute Cold Exposure; Positron Emission Tomography (PET) +5 more
    PhaseNot applicable
    Registry statusCompleted

  • A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma

    NCT05448404 · start 2022-03-08

    Registered record
    Registry ID
    NCT05448404
    Conditions
    Multiple Myeloma
    Interventions
    18F-PSMA-1007; 18F-FDG
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2022-03-08
    Completion
    2023-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    Intervention18F-PSMA-1007; 18F-FDG
    PhaseNot applicable
    Registry statusUnknown

  • Usefulness of 18F-FDG PET/CT in the Initial Staging and Surveillance of Endometrial Cancer Patients

    NCT05056259 · start 2022-01-01

    Registered record
    Registry ID
    NCT05056259
    Conditions
    Endometrial Cancer
    Interventions
    18F-FDG PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2022-01-01
    Completion
    2023-10
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    Intervention18F-FDG PET/CT
    PhaseNot recorded
    Registry statusUnknown

  • PET Imaging of Systemic Sclerosis Using FDG and 68Ga-DOTA-Siglec-9

    NCT05108857 · start 2021-11-29

    Registered record
    Registry ID
    NCT05108857
    Conditions
    Systemic Sclerosis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Enrolling by invitation
    Start
    2021-11-29
    Completion
    2026-12-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSystemic Sclerosis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusEnrolling by invitation

  • PET-imaging of Unruptured Intracranial Aneurysm Inflammation

    NCT04715503 · start 2021-01-14

    Registered record
    Registry ID
    NCT04715503
    Conditions
    Intracranial Aneurysm; Cerebral Aneurysm; Inflammation
    Interventions
    PET imaging, 18F-FDG; PET imaging, 68Ga-DOTANOC
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-01-14
    Completion
    2022-10
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Aneurysm; Cerebral Aneurysm; Inflammation
    InterventionPET imaging, 18F-FDG; PET imaging, 68Ga-DOTANOC
    PhaseNot applicable
    Registry statusUnknown

  • Combined [18F]-FDG PET-MRI in Diagnostics and Surveillance of Small Bowel Crohn's Disease

    NCT06796959 · start 2020-08-01

    Registered record
    Registry ID
    NCT06796959
    Conditions
    Small Bowel Crohn' s Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-08-01
    Completion
    2024-10-31
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Bowel Crohn' s Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Study for Quantitative Analysis of the Recovered COVID-19 Patients by 18F-FDG-PET/CT

    NCT04519255 · start 2020-07-01

    Registered record
    Registry ID
    NCT04519255
    Conditions
    PET/CT; COVID-19; Respiratory Function; Inflammatory Lesions
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-07-01
    Completion
    2023-07-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPET/CT; COVID-19; Respiratory Function; Inflammatory Lesions
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer

    NCT04281641 · start 2020-04-21

    Registered record
    Registry ID
    NCT04281641
    Conditions
    HER2-positive Breast Cancer
    Interventions
    TCHP
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2020-04-21
    Completion
    2030-04-30
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer
    InterventionTCHP
    PhaseNot applicable
    Registry statusRecruiting

  • Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

    NCT04166318 · start 2020-01-02

    Registered record
    Registry ID
    NCT04166318
    Conditions
    Anal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Canal Squamous Cell Carcinoma; Anal Margin Squamous Cell Carcinoma; Stage I Anal Cancer AJCC v8; Stage IIA Anal Cancer AJCC v8
    Interventions
    Biopsy; Biospecimen Collection; Capecitabine; Computed Tomography; Fludeoxyglucose F-18; Fluorouracil; Intensity-Modulated Radiation Therapy; Magnetic Resonance Imaging; Mitomycin; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2020-01-02
    Completion
    2029-12-31
    Enrolment
    252

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnal Basaloid Carcinoma; Anal Canal Cloacogenic Carcinoma; Anal Canal Squamous Cell Carcinoma; Anal Margin Squamous Cell Carcinoma +2 more
    InterventionBiopsy; Biospecimen Collection; Capecitabine; Computed Tomography +8 more
    PhasePhase 2
    Registry statusActive not recruiting

  • De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

    NCT03952585 · start 2019-10-09

    Registered record
    Registry ID
    NCT03952585
    Conditions
    Basaloid Squamous Cell Carcinoma; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma; Papillary Squamous Cell Carcinoma; Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Squamous Cell Carcinoma
    Interventions
    Biopsy Procedure; Biospecimen Collection; Cisplatin; Computed Tomography; Fludeoxyglucose F-18; Image Guided Radiation Therapy; Intensity-Modulated Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2019-10-09
    Completion
    2026-12-11
    Enrolment
    384

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBasaloid Squamous Cell Carcinoma; Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8; Oropharyngeal Squamous Cell Carcinoma +4 more
    InterventionBiopsy Procedure; Biospecimen Collection; Cisplatin; Computed Tomography +8 more
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • F-18 FDG- PETCT in Staging and Recurrent Colorectal Cancer

    NCT03572595 · start 2018-07-01

    Registered record
    Registry ID
    NCT03572595
    Conditions
    Colo-rectal Cancer; Recurrence
    Interventions
    F-18 FDG-PET/CT
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2020-02-01
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColo-rectal Cancer; Recurrence
    InterventionF-18 FDG-PET/CT
    PhaseNot recorded
    Registry statusUnknown

  • Evaluation of a Metabolic Preparation by a Low-carbohydrate Diet as Atkins-diet to Help in Detecting Infective Endocarditis by 18F-FDG PET

    NCT03465098 · start 2018-03-19

    Registered record
    Registry ID
    NCT03465098
    Conditions
    Infective Endocarditis
    Interventions
    Strict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2018-03-19
    Completion
    2021-08-03
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfective Endocarditis
    InterventionStrict low carbohydrate diet (< 3gr/day of carbohydrate) before a 18F-FDG PET/CT
    PhaseNot applicable
    Registry statusCompleted

  • PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients

    NCT03279393 · start 2017-11-28

    Registered record
    Registry ID
    NCT03279393
    Conditions
    PTSD; Trauma; Healthy
    Interventions
    fluorodeoxyglucose (FDG)-PET/MRI
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-11-28
    Completion
    2023-02-14
    Enrolment
    190

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPTSD; Trauma; Healthy
    Interventionfluorodeoxyglucose (FDG)-PET/MRI
    PhaseEarly phase 1
    Registry statusCompleted